Research at Oslo University Hospital

 

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

 

Latest news

New insight into late effects after cancer treatment presented by the Norwegian Cancer Society

 
Cecilie Kiserud
Cecilie Kiserud

The Norwegian Cancer Society present research they support regularly, in a popular science form, and they have recently published a feature article on late effects after cancer treatment.
Cecilie Kiserud, head of the National Advisory Unit on Late Effects after Cancer Treatment at the Department of Oncology, has been interviewed about their research activites and new insight into life after cancer, a field that has gained more attention the recent years.

 
 

Study on replication fork stability from Skarstad group published in Nucleic Acids Research

 
First authors Ida B. Pedersen (left) and Emily Helgesen
First authors Ida B. Pedersen (left) and Emily Helgesen

Replication forks must be stabilized in order to avoid DNA breakage and recombination. In a study recently published in Nucleic Acids Research entitled “SeqA structures behind Escherichia coli replication forks affect replication elongation and restart mechanisms“ researchers in the Skarstad group show that double strand breaks are generated in the absence of fork-trailing SeqA structures and that cells then have lost the ability to perform direct (RecA-independent) restart of replication forks. The two first authors are Ida Benedikte Pedersen and Emily Helgesen (photo).

 
 

NORMENT researchers contribute to PLOS Medicine article on genetic assessment of age-associated Alzheimer's disease risk

 
Ole Andreassen, Centre Director NORMENT
Ole Andreassen, Centre Director NORMENT

Researchers from the NORMENT KG Jebsen Centre for Psychosis Research at OUS and UiO have participated in a large international consortium to develop a novel tool for genetic risk prediction in Alzheimer’s disease. This is based on a long standing collaboration between the statistical genetics team at NORMENT and the University of California San Diego (UCSD) Center for Translational Imaging and Precision Medicine. The scientists are now working to improve the method for mental illness applications.
The results have recently been published in Plos Medicine (journal impact factor 13.6). The study has received widespread attention, including articles in major international newspapers.

 
 

The AACR-WICR Friend Lectureship presented to Anne-Lise Børresen-Dale

 
A-L. Børresen-Dale
A-L. Børresen-Dale

The American Association for Cancer Research (AACR) - Women in Cancer Research (WICR) Charlotte Friend Memorial Lectureship was established in 1998 in honour of renowned virologist and discoverer of the Friend virus, Dr. Charlotte Friend. The WICR Friend Lectureship is presented to an outstanding scientist who has made meritorious contributions to the field of cancer research and who has, through leadership or by example, furthered the advancement of women in science.
Anne-Lise Børresen-Dale, professor emerita at the Department of Cancer Genetics at the Institute for Cancer Research, OUH, has been chosen as the 20th Annual Award Recipient. Her award lecture will be held on April 3rd in the Washington Convention Center.

 
 

A retrospective pooled biomarker study to predict overall survival beyond the TNM system

 
Researchers Stine Aske Danielsen and Anita Sveen.
Researchers Stine Aske Danielsen and Anita Sveen.

K.G.Jebsen Colorectal Cancer Research Centre scientists participated with data from patients admitted to OUH in a multicenter study of >7000 stage II and III CRC recently reported in Annals of Oncology (Dienstmann et al).
Incorporation of MSI, BRAFV600E and KRAS mutation status to overall survival models with TNM staging improves the ability to precisely prognosticate in stage II and III CC patients, but only modestly increases prediction accuracy in multivariable models that include clinicopathological features, particularly in chemotherapy-treated patients.

 
 

CanCell – a new Centre of Excellence – will reprogram cancer cells

 

“Centre for Cancer Cell Reprogramming”, affiliated with the Institute of Clinical Medicine at University of Oslo, has been funded by the Research Council of Norway as a new Centre of Excellence.

 
 

New group leader at the Institute for Cancer Research:

Jørgen Wesche appointed group leader for the Mesenchymal Cancer Biology Group at the Department of Tumor Biology

 
Jørgen Wesche
Jørgen Wesche

Jørgen Wesche earned his PhD in Sjur Olsnes's group in 2001, studying intracellular transport and membrane translocation. During his postdoctoral training, spending some time at Institute Curie in Paris, he has changed his focus towards problems with more translational relevance, specializing in live cell imaging, fibroblast growth factor receptor (FGFR) signaling and importance of FGFR in cell migration/invasion. Aberrations in FGFR signaling are found in several types of sarcoma and that´s the main reason way Jørgen started to get interested in sarcoma biology and treatment. He has several exciting ideas on how to further develop his research into more translational/clinical relevance.

 
 

King Olav V´s Cancer Research Prize to Per O. Seglen

Prestigious research prize from the Norwegian Cancer Society to pioneer in autophagy research

 
Per O. Seglen (left) and 2016 Nobel laureate Yoshinori Ohsumi
Per O. Seglen (left) and 2016 Nobel laureate Yoshinori Ohsumi

Professor Per Ottar Seglen, formerly head of the Proteomics & Mammalian Cell Biology Section at the Institute for Cancer Research, OUH, currently a guest researcher at NCMM, has been awarded the prestigious King Olav V’s prize for Cancer Research 2017.

The award, formally announced by the Norwegian Cancer Society today, is recognized as one of the Norwegian cancer research community’s most respected prizes. Professor Seglen has been awarded the prize in recognition of his ground-breaking research into autophagic-lysosomal protein degradation and its relationship to cancer.

The prize will be officially presented by King Harald V, on behalf of the Cancer Society, at a special ceremony on 6 June 2017. The prize is NOK 1 million.

 
 

Announcement:

Course in Health Economics and Economic Evaluation

 

Are you concerned about costs, resource use, health-related quality of life and economic evaluation?

The Health Economics Team from the Research Support Services at Oslo University Hospital invites you to participate in an annual course in health economics 14th of June 2017. The course will cover basic principles of health economic evaluation. We have also prepared a quiz to enable you to test what you have learned.

Welcome!
Team health economics

 
 

OUH research seminar, Monday, March 6th 14:30

Health after transplantation

 

Welcome to the next Oslo University Hospital research seminar entitled "Health after transplantation".

Time: Monday, March 6th, 2017, at 14:30 – 16:00.
Place: Red Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo.